PE20211795A1 - Compuestos heteroaril tetraciclicos - Google Patents
Compuestos heteroaril tetraciclicosInfo
- Publication number
- PE20211795A1 PE20211795A1 PE2020001766A PE2020001766A PE20211795A1 PE 20211795 A1 PE20211795 A1 PE 20211795A1 PE 2020001766 A PE2020001766 A PE 2020001766A PE 2020001766 A PE2020001766 A PE 2020001766A PE 20211795 A1 PE20211795 A1 PE 20211795A1
- Authority
- PE
- Peru
- Prior art keywords
- compounds
- heteroaryl
- fluoroalkyl
- halo
- alkoxy
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/14—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
La presente invencion se refiere a compuestos heteroarilo tetraciclicos de formula (I); en donde, el anillo A se selecciona entre fenilo y heteroarilo biciclico; R1 en cada caso se selecciona independientemente entre alquilo C1-4, halo, hidroxi, alcoxi C1-4, entre otros; R2 es ciano, halo, alquilo C1-4, alcoxi C1-4 o fluoroalquilo C1-3; R3 es F, Me, Et, MeO o fluoroalquilo C1-2; R4 y R5 son independientemente, H o Me; R6 es H o CH2NMe2; b es 0, 1, 2 o 3; Y es CH2 o CH2CH2. Dichos compuestos inhiben las proteinas RAS mutantes G12C. Un compuesto seleccionado es 7-[(8aS)-10-acriloil-6-cloro-4-fluoro-8,8a,9,10,11,12hexahidropirazino[2',1':3,4][1,4]oxazepino [5,6,7-de]quinazolin-5-il]-6-metil-2,3-dihidro-1H-isoindol-1-ona. Tambien refiere a procesos e intermedios usados para su preparacion, a composiciones farmaceuticas que los contienen; siendo utiles en el tratamiento de trastornos proliferativos celulares y como antitumoral.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862668321P | 2018-05-08 | 2018-05-08 | |
| US201862754814P | 2018-11-02 | 2018-11-02 | |
| PCT/EP2019/061754 WO2019215203A1 (en) | 2018-05-08 | 2019-05-07 | Tetracyclic heteroaryl compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20211795A1 true PE20211795A1 (es) | 2021-09-09 |
Family
ID=66484036
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2020001766A PE20211795A1 (es) | 2018-05-08 | 2019-05-07 | Compuestos heteroaril tetraciclicos |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US11407765B2 (es) |
| EP (1) | EP3790884A1 (es) |
| JP (1) | JP7138724B2 (es) |
| KR (1) | KR20210006948A (es) |
| CN (1) | CN112074520A (es) |
| AU (1) | AU2019267008B2 (es) |
| BR (1) | BR112020021467A2 (es) |
| CA (1) | CA3098261A1 (es) |
| CL (1) | CL2020002866A1 (es) |
| CO (1) | CO2020013564A2 (es) |
| CR (1) | CR20200532A (es) |
| DO (1) | DOP2020000201A (es) |
| EC (1) | ECSP20070854A (es) |
| JO (1) | JOP20200281A1 (es) |
| MA (1) | MA52560A (es) |
| MX (1) | MX2020011910A (es) |
| NI (1) | NI202000078A (es) |
| PE (1) | PE20211795A1 (es) |
| PH (1) | PH12020551870A1 (es) |
| SG (1) | SG11202010953QA (es) |
| TW (1) | TW202012415A (es) |
| UY (1) | UY38221A (es) |
| WO (1) | WO2019215203A1 (es) |
Families Citing this family (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7453989B2 (ja) * | 2019-03-05 | 2024-03-21 | アストラゼネカ・アクチエボラーグ | 抗癌剤として有用な縮合三環式化合物 |
| KR20220012255A (ko) * | 2019-04-28 | 2022-02-03 | 젠플리트 테라퓨틱스 (상하이) 아이엔씨. | 옥사아자퀴나졸린-7(8h)-케톤 화합물, 이의 제조 방법 및 이의 약학적 응용 |
| WO2021091967A1 (en) | 2019-11-04 | 2021-05-14 | Revolution Medicines, Inc. | Ras inhibitors |
| KR20220109407A (ko) | 2019-11-04 | 2022-08-04 | 레볼루션 메디슨즈, 인크. | Ras 억제제 |
| TW202132316A (zh) | 2019-11-04 | 2021-09-01 | 美商銳新醫藥公司 | Ｒａｓ抑制劑 |
| EP4065231A1 (en) * | 2019-11-27 | 2022-10-05 | Revolution Medicines, Inc. | Covalent ras inhibitors and uses thereof |
| HRP20221301T1 (hr) * | 2019-12-11 | 2022-12-23 | Eli Lilly And Company | Inhibitori kras g12c |
| TWI799871B (zh) * | 2020-05-27 | 2023-04-21 | 大陸商勁方醫藥科技(上海)有限公司 | 三環并環類化合物，其製法與醫藥上的用途 |
| CA3183032A1 (en) | 2020-06-18 | 2021-12-23 | Mallika Singh | Methods for delaying, preventing, and treating acquired resistance to ras inhibitors |
| CN113980032B (zh) * | 2020-07-27 | 2023-06-16 | 江苏恒瑞医药股份有限公司 | 稠合四环类衍生物、其制备方法及其在医药上的应用 |
| CA3187757A1 (en) | 2020-09-03 | 2022-03-24 | Ethan AHLER | Use of sos1 inhibitors to treat malignancies with shp2 mutations |
| CA3194067A1 (en) | 2020-09-15 | 2022-03-24 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2022133345A1 (en) | 2020-12-18 | 2022-06-23 | Erasca, Inc. | Tricyclic pyridones and pyrimidones |
| CN114685531A (zh) * | 2020-12-25 | 2022-07-01 | 武汉誉祥医药科技有限公司 | 四并环化合物及其药物组合物和应用 |
| KR20230145078A (ko) * | 2021-02-09 | 2023-10-17 | 제넨테크, 인크. | 테트라시클릭 옥사제핀 화합물 및 이의 용도 |
| WO2022188729A1 (en) * | 2021-03-07 | 2022-09-15 | Jacobio Pharmaceuticals Co., Ltd. | Fused ring derivatives useful as kras g12d inhibitors |
| EP4310091A1 (en) * | 2021-03-17 | 2024-01-24 | Genfleet Therapeutics (Shanghai) Inc. | Pyrimidine-fused cyclic compound, preparation method therefor and use thereof |
| CN117083281A (zh) * | 2021-03-24 | 2023-11-17 | 南京明德新药研发有限公司 | 嘧啶并杂环类化合物及其应用 |
| CN116113632A (zh) * | 2021-03-30 | 2023-05-12 | 浙江海正药业股份有限公司 | 杂环类衍生物、其制备方法及其医药上的用途 |
| JP2024513881A (ja) * | 2021-04-08 | 2024-03-27 | ジェネンテック， インコーポレイテッド | オキサゼピン化合物及びがんの治療におけるその使用 |
| IL308193A (en) | 2021-05-05 | 2024-01-01 | Revolution Medicines Inc | RAS inhibitors |
| CN117616031A (zh) | 2021-05-05 | 2024-02-27 | 锐新医药公司 | 用于治疗癌症的ras抑制剂 |
| JP2024522766A (ja) * | 2021-06-21 | 2024-06-21 | 江蘇恒瑞医薬股▲ふん▼有限公司 | 縮合四環系化合物、その調製方法及びその医薬的応用 |
| CA3224284A1 (en) * | 2021-07-02 | 2023-01-05 | Feng Wang | Kras g12d inhibitor and use thereof |
| WO2023001123A1 (zh) * | 2021-07-19 | 2023-01-26 | 上海艾力斯医药科技股份有限公司 | 新型吡啶并嘧啶衍生物 |
| CN117242079A (zh) * | 2021-07-23 | 2023-12-15 | 苏州赞荣医药科技有限公司 | Kras g12d抑制剂和其用途 |
| TW202315626A (zh) * | 2021-08-31 | 2023-04-16 | 大陸商勁方醫藥科技(上海)有限公司 | 嘧啶并環類化合物及其製法和用途 |
| IL309086A (en) | 2021-09-01 | 2024-02-01 | Novartis Ag | Pharmaceutical combinations involving a tonic inhibitor and its uses for the treatment of cancer |
| EP4389751A1 (en) | 2021-09-03 | 2024-06-26 | Kumquat Biosciences Inc. | Heterocyclic compounds and uses thereof |
| KR20240070619A (ko) * | 2021-09-27 | 2024-05-21 | 자코바이오 파마슈티칼스 컴퍼니 리미티드 | 폴리사이클릭 융합 고리 유도체 및 이의 용도 |
| AR127308A1 (es) | 2021-10-08 | 2024-01-10 | Revolution Medicines Inc | Inhibidores ras |
| CA3234517A1 (en) | 2021-10-22 | 2023-04-27 | Xin Li | Nitrogen-containing tetracyclic compound, preparation method therefor, and medical use thereof |
| WO2023072297A1 (zh) * | 2021-11-01 | 2023-05-04 | 江苏恒瑞医药股份有限公司 | 含氮的四环化合物、其制备方法及其在医药上的应用 |
| WO2023103906A1 (zh) * | 2021-12-07 | 2023-06-15 | 贝达药业股份有限公司 | Kras g12d抑制剂及其在医药上的应用 |
| WO2023114954A1 (en) | 2021-12-17 | 2023-06-22 | Genzyme Corporation | Pyrazolopyrazine compounds as shp2 inhibitors |
| TW202333800A (zh) | 2021-12-28 | 2023-09-01 | 英商阿斯特捷利康英國股份有限公司 | 抗體-藥物結合物及rasg12c抑制劑之組合 |
| EP4227307A1 (en) | 2022-02-11 | 2023-08-16 | Genzyme Corporation | Pyrazolopyrazine compounds as shp2 inhibitors |
| CN114539073A (zh) * | 2022-02-18 | 2022-05-27 | 郑州萃智医药科技有限公司 | 3-溴-2-氯-4,6-二氟苯胺的合成方法 |
| WO2023172940A1 (en) | 2022-03-08 | 2023-09-14 | Revolution Medicines, Inc. | Methods for treating immune refractory lung cancer |
| WO2023205701A1 (en) | 2022-04-20 | 2023-10-26 | Kumquat Biosciences Inc. | Macrocyclic heterocycles and uses thereof |
| WO2023240263A1 (en) | 2022-06-10 | 2023-12-14 | Revolution Medicines, Inc. | Macrocyclic ras inhibitors |
| WO2024031088A1 (en) * | 2022-08-05 | 2024-02-08 | Kumquat Biosciences Inc. | Heterocyclic compounds and uses thereof |
| WO2024032703A1 (en) * | 2022-08-11 | 2024-02-15 | Beigene, Ltd. | Heterocyclic compounds, compositions thereof, and methods of treatment therewith |
| WO2024041621A1 (en) * | 2022-08-25 | 2024-02-29 | Jacobio Pharmaceuticals Co., Ltd. | K-ras mutant protein inhibitors |
| WO2024063578A1 (ko) * | 2022-09-23 | 2024-03-28 | 일동제약(주) | 신규한 테트라헤테로사이클 화합물 |
| WO2024063576A1 (ko) * | 2022-09-23 | 2024-03-28 | 일동제약(주) | Kras 저해 물질로서 신규한 퀴나졸린 화합물 |
| WO2024085661A1 (en) * | 2022-10-18 | 2024-04-25 | Ildong Pharmaceutical Co., Ltd. | Novel triheterocyclic compounds |
| WO2024102421A2 (en) | 2022-11-09 | 2024-05-16 | Revolution Medicines, Inc. | Compounds, complexes, and methods for their preparation and of their use |
| WO2024120419A1 (en) * | 2022-12-06 | 2024-06-13 | Zai Lab (Shanghai) Co., Ltd. | Fused tetracyclic compounds as kras g12d modulators and uses thereof |
Family Cites Families (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013155223A1 (en) | 2012-04-10 | 2013-10-17 | The Regents Of The University Of California | Compositions and methods for treating cancer |
| WO2014143659A1 (en) | 2013-03-15 | 2014-09-18 | Araxes Pharma Llc | Irreversible covalent inhibitors of the gtpase k-ras g12c |
| MX364438B (es) | 2013-03-15 | 2019-04-26 | Araxes Pharma Llc | Inhibidores covalentes de kras g12c. |
| CN106488910B (zh) | 2013-10-10 | 2020-07-31 | 亚瑞克西斯制药公司 | Kras g12c的抑制剂 |
| JO3556B1 (ar) | 2014-09-18 | 2020-07-05 | Araxes Pharma Llc | علاجات مدمجة لمعالجة السرطان |
| EP3197870B1 (en) | 2014-09-25 | 2020-08-19 | Araxes Pharma LLC | Inhibitors of kras g12c mutant proteins |
| AU2016245864C1 (en) | 2015-04-10 | 2021-09-09 | Araxes Pharma Llc | Substituted quinazoline compounds and methods of use thereof |
| JP6789239B2 (ja) | 2015-04-15 | 2020-11-25 | アラクセス ファーマ エルエルシー | Ｋｒａｓの縮合三環系インヒビターおよびその使用の方法 |
| JP6869947B2 (ja) | 2015-07-22 | 2021-05-12 | アラクセス ファーマ エルエルシー | 置換キナゾリン化合物ならびにそのｇ１２ｃ変異ｋｒａｓ、ｈｒａｓおよび／またはｎｒａｓタンパク質の阻害剤としての使用 |
| EP3356349A1 (en) | 2015-09-28 | 2018-08-08 | Araxes Pharma LLC | Inhibitors of kras g12c mutant proteins |
| EP3356347A1 (en) | 2015-09-28 | 2018-08-08 | Araxes Pharma LLC | Inhibitors of kras g12c mutant proteins |
| EP3356354A1 (en) | 2015-09-28 | 2018-08-08 | Araxes Pharma LLC | Inhibitors of kras g12c mutant proteins |
| EP3356339A1 (en) | 2015-09-28 | 2018-08-08 | Araxes Pharma LLC | Inhibitors of kras g12c mutant proteins |
| WO2017058728A1 (en) | 2015-09-28 | 2017-04-06 | Araxes Pharma Llc | Inhibitors of kras g12c mutant proteins |
| US10647703B2 (en) | 2015-09-28 | 2020-05-12 | Araxes Pharma Llc | Inhibitors of KRAS G12C mutant proteins |
| EP3356359B1 (en) | 2015-09-28 | 2021-10-20 | Araxes Pharma LLC | Inhibitors of kras g12c mutant proteins |
| WO2017087528A1 (en) | 2015-11-16 | 2017-05-26 | Araxes Pharma Llc | 2-substituted quinazoline compounds comprising a substituted heterocyclic group and methods of use thereof |
| WO2017201161A1 (en) | 2016-05-18 | 2017-11-23 | Mirati Therapeutics, Inc. | Kras g12c inhibitors |
| CN110036010A (zh) | 2016-09-29 | 2019-07-19 | 亚瑞克西斯制药公司 | Kras g12c突变蛋白的抑制剂 |
| WO2018068017A1 (en) | 2016-10-07 | 2018-04-12 | Araxes Pharma Llc | Heterocyclic compounds as inhibitors of ras and methods of use thereof |
| KR102592246B1 (ko) | 2016-12-22 | 2023-10-23 | 암젠 인크 | 폐암, 췌장암 또는 대장암을 치료하기 위한 kras g12c 억제제로서의 벤즈이소티아졸, 이소티아졸로[3,4-b]피리딘, 퀴나졸린, 프탈라진, 피리도[2,3-d]피리다진 및 피리도[2,3-d]피리미딘 유도체 |
| EP3573967A1 (en) | 2017-01-26 | 2019-12-04 | Araxes Pharma LLC | Fused hetero-hetero bicyclic compounds and methods of use thereof |
| US11136308B2 (en) | 2017-01-26 | 2021-10-05 | Araxes Pharma Llc | Substituted quinazoline and quinazolinone compounds and methods of use thereof |
| EP3573964A1 (en) | 2017-01-26 | 2019-12-04 | Araxes Pharma LLC | Benzothiophene and benzothiazole compounds and methods of use thereof |
| WO2018140512A1 (en) | 2017-01-26 | 2018-08-02 | Araxes Pharma Llc | Fused bicyclic benzoheteroaromatic compounds and methods of use thereof |
| EP3573966A1 (en) | 2017-01-26 | 2019-12-04 | Araxes Pharma LLC | Fused n-heterocyclic compounds and methods of use thereof |
| US11279689B2 (en) | 2017-01-26 | 2022-03-22 | Araxes Pharma Llc | 1-(3-(6-(3-hydroxynaphthalen-1-yl)benzofuran-2-yl)azetidin-1 yl)prop-2-en-1-one derivatives and similar compounds as KRAS G12C modulators for treating cancer |
| JOP20190186A1 (ar) | 2017-02-02 | 2019-08-01 | Astellas Pharma Inc | مركب كينازولين |
| CN110603258A (zh) | 2017-05-11 | 2019-12-20 | 阿斯利康(瑞典)有限公司 | 抑制g12c突变型ras蛋白的杂芳基化合物 |
| JOP20190272A1 (ar) | 2017-05-22 | 2019-11-21 | Amgen Inc | مثبطات kras g12c وطرق لاستخدامها |
| US10736897B2 (en) | 2017-05-25 | 2020-08-11 | Araxes Pharma Llc | Compounds and methods of use thereof for treatment of cancer |
| KR20200010306A (ko) | 2017-05-25 | 2020-01-30 | 아락세스 파마 엘엘씨 | Kras의 공유적 억제제 |
| US11639346B2 (en) | 2017-05-25 | 2023-05-02 | Araxes Pharma Llc | Quinazoline derivatives as modulators of mutant KRAS, HRAS or NRAS |
| EP4141005B1 (en) | 2017-09-08 | 2024-04-03 | Amgen Inc. | Inhibitors of kras g12c and methods of using the same |
| RS64182B1 (sr) | 2017-11-15 | 2023-05-31 | Mirati Therapeutics Inc | Inhibitori kras g12c |
| US10597405B2 (en) | 2017-12-08 | 2020-03-24 | Astrazeneca Ab | Chemical compounds |
| TW201942115A (zh) | 2018-02-01 | 2019-11-01 | 美商輝瑞股份有限公司 | 作為抗癌藥之經取代的喹唑啉和吡啶並嘧啶衍生物 |
| TW201942116A (zh) | 2018-02-09 | 2019-11-01 | 美商輝瑞股份有限公司 | 作為抗癌劑之四氫喹唑啉衍生物 |
-
2019
- 2019-05-03 TW TW108115329A patent/TW202012415A/zh unknown
- 2019-05-07 CA CA3098261A patent/CA3098261A1/en active Pending
- 2019-05-07 US US17/053,400 patent/US11407765B2/en active Active
- 2019-05-07 CR CR20200532A patent/CR20200532A/es unknown
- 2019-05-07 SG SG11202010953QA patent/SG11202010953QA/en unknown
- 2019-05-07 EP EP19723368.7A patent/EP3790884A1/en not_active Withdrawn
- 2019-05-07 KR KR1020207035034A patent/KR20210006948A/ko unknown
- 2019-05-07 JP JP2020560800A patent/JP7138724B2/ja active Active
- 2019-05-07 MA MA052560A patent/MA52560A/fr unknown
- 2019-05-07 CN CN201980030143.8A patent/CN112074520A/zh active Pending
- 2019-05-07 AU AU2019267008A patent/AU2019267008B2/en not_active Expired - Fee Related
- 2019-05-07 JO JOP/2020/0281A patent/JOP20200281A1/ar unknown
- 2019-05-07 MX MX2020011910A patent/MX2020011910A/es unknown
- 2019-05-07 WO PCT/EP2019/061754 patent/WO2019215203A1/en unknown
- 2019-05-07 PE PE2020001766A patent/PE20211795A1/es unknown
- 2019-05-07 BR BR112020021467-1A patent/BR112020021467A2/pt not_active Application Discontinuation
- 2019-05-08 UY UY38221A patent/UY38221A/es not_active Application Discontinuation
-
2020
- 2020-10-28 CO CONC2020/0013564A patent/CO2020013564A2/es unknown
- 2020-11-04 DO DO2020000201A patent/DOP2020000201A/es unknown
- 2020-11-05 PH PH12020551870A patent/PH12020551870A1/en unknown
- 2020-11-05 CL CL2020002866A patent/CL2020002866A1/es unknown
- 2020-11-06 NI NI202000078A patent/NI202000078A/es unknown
- 2020-11-06 EC ECSENADI202070854A patent/ECSP20070854A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| NI202000078A (es) | 2021-02-16 |
| WO2019215203A1 (en) | 2019-11-14 |
| US20210221823A1 (en) | 2021-07-22 |
| MA52560A (fr) | 2021-03-17 |
| CN112074520A (zh) | 2020-12-11 |
| US11407765B2 (en) | 2022-08-09 |
| CO2020013564A2 (es) | 2020-11-10 |
| AU2019267008A1 (en) | 2021-01-07 |
| SG11202010953QA (en) | 2020-12-30 |
| DOP2020000201A (es) | 2020-11-30 |
| EP3790884A1 (en) | 2021-03-17 |
| TW202012415A (zh) | 2020-04-01 |
| JP7138724B2 (ja) | 2022-09-16 |
| CL2020002866A1 (es) | 2021-02-12 |
| BR112020021467A2 (pt) | 2021-01-19 |
| JP2021532061A (ja) | 2021-11-25 |
| KR20210006948A (ko) | 2021-01-19 |
| UY38221A (es) | 2019-10-31 |
| ECSP20070854A (es) | 2020-12-31 |
| JOP20200281A1 (ar) | 2020-11-05 |
| MX2020011910A (es) | 2021-01-29 |
| PH12020551870A1 (en) | 2021-07-26 |
| AU2019267008B2 (en) | 2022-02-17 |
| CR20200532A (es) | 2020-12-23 |
| CA3098261A1 (en) | 2019-11-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20211795A1 (es) | Compuestos heteroaril tetraciclicos | |
| CL2020002419A1 (es) | Inhibidores de fosfatasa shp2 y métodos de uso de los mismos | |
| DOP2022000278A (es) | Inhibidores de cisteína proteasas y sus métodos de uso | |
| ECSP19047936A (es) | Imidazopirrolopiridina como inhibidores de la familia de quinasas jak | |
| NI201900060A (es) | Inhibidores de moléculas pequeñas de la familia de quinasa jak | |
| AR044402A1 (es) | Compuestos heterociclicos y su uso como inmunodepresores. composiciones farmaceuticas que los contienen. | |
| GEP20217242B (en) | Pyrazolo[1,5-a]pyrazin-4-yl derivatives as jak-inhibitors | |
| ECSP077170A (es) | Moduladores de receptores acetilcolina nicotinicos alfa 7 y sus usos terapeuticos | |
| AR048912A1 (es) | Inmunoglobulinas anti-nogo | |
| AR070221A1 (es) | Derivados de ftalazinona inhibidores de polimerasas, composiciones farmaceuticas que los contienen y usos de los mismos para prevenir y/o tratar tumores cancerigenos,lesiones isquemicas y otras enfermedades asociadas. | |
| UY39477A (es) | Compuestos espiro heterocíclicos y métodos de uso | |
| ECSP20080817A (es) | Inhibidores de moléculas pequeñas de la familia de quinasas jak | |
| AR048501A1 (es) | Compuesto de benzoazabicicloheptano dimerico, composicion farmaceutica que lo comprende y su uso para prepararla | |
| CO2017008809A2 (es) | Compuestos de benzoxaborol y uso de los mismos | |
| CO2022000749A2 (es) | Inhibidores de monoacilglicerol lipasa (magl) heterocíclicos | |
| CY1124346T1 (el) | ΠΑΡΑΓΩΓΑ ΧΡΩΜΑΝΙΟΥ, ΙΣΟΧΡΩΜΑΝΙΟΥ ΚΑΙ ΔΙΥΔΡΟΪΣΟΒΕΝΖΟΦΟΥΡΑΝΙΟΥ ΩΣ mGluR2-APNHTIKOI ΑΛΛΟΣΤΕΡΙΚΟΙ ΔΙΑΜΟΡΦΩΤΕΣ, ΣΥΝΘΕΣΕΙΣ, ΚΑΙ ΧΡΗΣΗ ΑΥΤΩΝ | |
| CL2021002621A1 (es) | Compuestos de hexahidro-1h-pirazino[1,2-a]pirazina para el tratamiento de una enfermedad autoinmunitaria | |
| PE20070167A1 (es) | COMPUESTOS 5H-BENZO[4,5]CICLOHEPTA[1,2-b]PIRIDINA COMO INHIBIDORES DE TIROSINA QUINASA | |
| ES2912223T3 (es) | Derivados de éter cíclico de pirazolo[1,5-a]pirimidin-3-carboxiamida | |
| AR111176A1 (es) | Derivados pirazol[1,5-a]pirimidina sustituidos con alicíclicos farmacológicamente activos | |
| PE20210403A1 (es) | Derivados de 10-(di(fenil)metil)-4-hidroxi-8,9,9a,10-tetrahidro-7h-pirrolo [1',2':4,5]pirazino[1,2-b]piridazina-3,5-diona y compuestos relacionados como inhibidores de la replicacion del ortomixovirus para el tratamiento de la influenza | |
| AR044275A1 (es) | Uso de derivados de sulfonamidas para la fabricacion de un medicamento para la profilaxis y/o tratamiento de las disfunciones alimentarias | |
| CU24543B1 (es) | Compuestos bicíclicos 5,6-fusionados y composiciones para el tratamiento de enfermedades parasitarias | |
| AR041994A1 (es) | 6-(2-halogenofenil)-triazolopirimidinas sustituidas | |
| AR036092A1 (es) | Un derivado de benzoxazepina, su uso y una composicion farmaceutica que lo comprende |